The Platform trial In COVID-19 priming and BOOsting (PICOBOO): The immunogenicity, reactogenicity and safety of seven licensed COVID-19 vaccines delivered as fifth dose or subsequent boosters in immunocompetent adults.

Comirnaty (tozinameran) - Pfizer, BioNTech

Vaxzevria (ChAdOx1-S recombinant) - University of Oxford, Emergent Biosolutions, Jenner Institute, Barinthus Bio, AstraZeneca

DoCo-Pro-RBD-1+MF59 - The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Monash University

http://www.ncbi.nlm.nih.gov/pubmed/42520645

A McKenzie; C C Blyth; C McCallum; C Tedja; F L Mordant; H Marshall; J A Marsh; K L Flanagan; K Subbarao; K Wilson; M C Tjiam; M Dymock; M J Estcourt; M Plebanski; McLeod C; P C M Williams; P Richmond; R B Thornton; S N Faust; S Nicholson; S Tansil; T Karapanagiotidis; T L Snelling; U Wadia; Z Ellis

Jul 29, 2026